Donanemab, with improved safety, efficacy, convenient dosing regime, and most importantly its ability to not only prevent but also clear plaques has the potential to redefine the treatment regime for Alzheimer’s patients.
With a comparable safety profile, Eli Lilly delivers on even the most basic outcomes essential for individuals with Alzheimer's disease, offering hope for improved quality of life and independence.
Eli Lilly’s donanemab, a frontrunner applicant for Alzheimer’s disease, recognizes and eliminates excess aberrant Amyloid-β (Aβ) proteins thus not only preventing the deposition of new plaques but also clearing the existing plaques, unlike any...
